Research programme: proteasome inhibitors - 4SC/ViroLogik

Drug Profile

Research programme: proteasome inhibitors - 4SC/ViroLogik

Alternative Names: 4SC-206; SC 68896; VL 01

Latest Information Update: 09 Oct 2013

Price : $50

At a glance

  • Originator 4SC
  • Developer 4SC; ViroLogik
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Hepatitis C; HIV infections
  • Discontinued Influenza A virus infections

Most Recent Events

  • 09 Oct 2013 VL 01 is still in preclinical trials for Hepatitis C and HIV infections in Germany
  • 17 Nov 2012 No development reported - Preclinical for Influenza A virus infections in Germany (unspecified route)
  • 08 Feb 2007 Preclinical trials in Cancer in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top